<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01668199</url>
  </required_header>
  <id_info>
    <org_study_id>NPJ5004-03/2011 (MET)</org_study_id>
    <nct_id>NCT01668199</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101</brief_title>
  <official_title>An Open-Label, Single-Dose, Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the mass balance recovery and pharmacokinetics of 14C TZP-101.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in plasma</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the pharmacokinetics of total radioactivity in plasma (Cmax, tmax, AUC, t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of parent TZP-101 in plasma</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the pharmacokinetics of parent TZP-101 in plasma (Cmax, tmax, AUC, t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in urine and faeces</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the Urine and faecal recovery of total radioactivity (Ae, Fe%, CLr)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total radioactivity in plasma</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the Total radioactivity in plasma/total radioactivity in whole blood ratio at selected timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total radioactivity of parent drug in plasma</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the Total radioactivity in plasma/parent drug in plasma ratio for selected PK parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Postoperative Ileus</condition>
  <arm_group>
    <arm_group_label>14C TZP-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TZP-101</intervention_name>
    <arm_group_label>14C TZP-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Males

          -  35-65 years of age

          -  Body Mass Index (BMI) of 18-32 kg/m2 or, if outside the range, considered not
             clinically significant by the investigator

          -  Body weight of 75-90kg

          -  Must be willing and able to communicate and participate in the whole study

          -  Must provide written informed consent

          -  Subject must agree to use adequate methods of contraception

        Exclusion Criteria:

          -  Participation in a clinical research study within the previous 3 moths or more than 3
             studies within the previous 12 months

          -  Participation in an ADE study within the previous 12 months

          -  History of any drug or alcohol abuse in the past 2 years

          -  Regular alcohol consumption &gt;21 units per week

          -  Current smokers and those who have smoked within the last 12 months, or a breath
             carbon monoxide (CO) reading of greater than 10ppm at screening

          -  Radiation exposure from clinical studies, including that from the present study,
             excluding background radiation including diagnostic X-rays and other medical
             exposures, exceeding 5 mSv in the last twelve months or 10 mSv in the last 5 years. No
             occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999,
             shall participate in the study

          -  Clinically significant abnormal biochemistry, haematology or urinalysis at screening
             as judged by the investigator

          -  Clinically significant abnormal physical findings, ECG or vital signs measurements at
             screening

          -  PR interval 220 ms at screening or on admission

          -  QTcB &gt;450 ms at screening or on admission

          -  Existence of any surgical or medical condition that might interfere with the
             absorption, distribution, metabolism or excretion of the IMP

          -  History or presence of significant cardiovascular, respiratory, gastrointestinal
             (especially peptic ulcer disease), neurological, psychiatric, metabolic, hepatic or
             renal problems as judged by the investigator

          -  Positive drugs of abuse test result

          -  Positive HBV, HCV or HIV results

          -  Use of prescription or non prescription drugs, including vitamins, herbal and dietary
             supplements (including St. John's Wort) within 14 days of the planned IMP
             administration unless in the opinion of the PI the medication will not interfere with
             study procedures or compromise study safety

          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

          -  Presence or history of allergy requiring treatment (seasonal allergic rhinitis
             (hayfever) is allowed unless it is active)

          -  Donation or loss of greater than 400 mL of blood within the previous three months

          -  Subjects receiving or requiring prohibited medication as described in Section 11

          -  Failure to satisfy the Investigator of fitness to participate for any other reason

          -  Poor venous access
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Evans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical, Mere Way, Ruddlington Fields, Nottingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

